Compare DAKT & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAKT | CTMX |
|---|---|---|
| Founded | 1968 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.7M | 977.1M |
| IPO Year | 1996 | 2015 |
| Metric | DAKT | CTMX |
|---|---|---|
| Price | $20.12 | $3.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $12.10 |
| AVG Volume (30 Days) | 244.2K | ★ 2.8M |
| Earning Date | 03-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $608,932,000.00 | $76,201,000.00 |
| Revenue This Year | $12.06 | N/A |
| Revenue Next Year | $9.16 | $7.61 |
| P/E Ratio | $26.33 | ★ $22.58 |
| Revenue Growth | ★ 6.89 | N/A |
| 52 Week Low | $13.05 | $1.72 |
| 52 Week High | $28.27 | $8.21 |
| Indicator | DAKT | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 54.01 | 39.49 |
| Support Level | $18.99 | $3.39 |
| Resistance Level | $20.55 | $3.91 |
| Average True Range (ATR) | 0.56 | 0.20 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 64.53 | 39.76 |
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.